Clinical Trial Update: Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/Phase 3 trial evaluating a combination of post-transplant cyclophosphamide, abatacept, vedolizumab, and baricitinib to prevent graft-versus-host disease…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Lymphoma
• Mixed Phenotype Acute Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Cytoxan (cyclophosphamide)
• Entyvio (vedolizumab)
• ORENCIA (ABATACEPT)
• Olumiant (baricitinib)

Snippet

Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING